Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
No takes yet. Share an insight, caveat, or question.
Richardson et al. (2003) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: